Search clinical trials for: Moderate to severe chronic pain

Total 475202 results

Mesoblast, Ltd.

Not yet recruiting

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain (HyaluronicAcid)

Degenerative Disc Disease
Merz Therapeutics GmbH

Recruiting

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury (PaiNT)

Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Bulgaria, Germany, Poland, France, Hungary, Spain
Cara Therapeutics, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Pruritus | Notalgia Paresthetica

United States, Poland, Spain, Canada, Germany
Stephen Robert Marder

Not yet recruiting

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Post Traumatic Stress Disorder

United States
Taipei Medical University Hospital

Recruiting

Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients

Hyperparathyroidism | Chronic Pain | Hemodialysis

Taiwan
AstraZeneca

Active, not recruiting

Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece (TRIAENA)

Pulmonary Disease, Chronic Obstructive (COPD)

Greece
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Pruritus | Notalgia Paresthetica

United States, Canada
Craig Hospital
Mayo Clinic; University of Alabama at Birmingham; Wayne State University; NYU Langone... and other collaborators

Completed

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

Pain | Traumatic Brain Injury

United States
Sorrento Therapeutics, Inc.

Active, not recruiting

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Knee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic

United States
University Health Network, Toronto
Unity Health Toronto; Women's College Hospital; MOUNT SINAI HOSPITAL

Completed

Sleep Health Program for Patients With Chronic Pain

Chronic Pain | Sleep | Sleep Disordered Breathing

Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Urologic Diseases | Urinary Bladder Diseases | Cystitis | Cystitis, Interstitial

United States, Canada
Braeburn Pharmaceuticals
Medpace, Inc.; Camurus AB

Completed

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (CAM2038)

Chronic Pain | Chronic Lower Back Pain

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

United States
Tris Pharma, Inc.

Terminated

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (CORAL)

Neoplasms | Pain | Chronic Pain

Croatia, Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Chile, Spain, United Kingdom
Nektar Therapeutics

Terminated

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

Moderate to Severe Chronic Pain

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer (COPE)

Cancer | Bone Neoplasms | Pain, Intractable

Italy, Spain, United States, Canada, France, Hungary, Poland, Sweden, Taiwan, Korea, Republic of, Philippines, Peru, Venezuela, Finland, Czechia, Egypt, Mexico, Russian Federation, Thailand
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Canada, Korea, Republic of
Purdue Pharma LP

Completed

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Chronic Nonmalignant and Nonneuropathic Pain

United States
Purdue Pharma LP

Completed

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

Chronic Low Back Pain

United States
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Pain | Knee Osteoarthritis

Austria, Croatia, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom
Eli Lilly and Company

Completed

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (AWARD-7)

Type 2 Diabetes | Chronic Kidney Disease

Mexico, United States, Hungary, Ukraine, Brazil, Spain, Romania, South Africa, Poland
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients

Chronic Pain

China
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain

Cancer Pain

China
Mundipharma Research GmbH & Co KG

Completed

Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation

Pain
Mundipharma Research GmbH & Co KG

Completed

A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain

Subjects With Moderate to Severe, Chronic Nonmalignant Pain
Mundipharma Research GmbH & Co KG

Completed

Oxycodone-naloxone in Relieving Opioid-related Constipation

Pain
Mundipharma Research GmbH & Co KG

Completed

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Pain | Cancer | Constipation

United Kingdom
Mundipharma Research GmbH & Co KG

Completed

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Chronic Osteoarthritis

Spain, Belgium, Finland, Czechia, Germany, Hungary
Egalet Ltd

Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Moderate-to-severe Chronic Noncancer Pain

United States
Egalet Ltd

Completed

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Moderate-to-severe Chronic Low Back Pain

United States
Janssen Scientific Affairs, LLC

Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Pain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or Knee

United States
Centrexion Therapeutics

Completed

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Osteoarthritis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Pfizer

Completed

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Low Back Pain | Chronic Pain | Analgesia

United States
Mundipharma Korea Ltd

Completed

An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)

Chronic Pain

Korea, Republic of
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States
Mundipharma Pte Ltd.
Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...

Completed

Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain

Osteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle Pain

Hong Kong, Korea, Republic of, Philippines
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Pain | Mononeuropathies | Neuralgia | Neuralgia, Postherpetic

United States, Spain, Belgium, Netherlands
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Pain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, Splitting

United States, France, Spain, Poland, Portugal
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Moderate to Severe Chronic Non-cancer Pain
Purdue Pharma LP

Completed

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Purdue Pharma LP

Completed

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Pain | Postherpetic Neuralgia

United States

3

Subscribe